Evogene Statistics
Total Valuation
Evogene has a market cap or net worth of $10.10 million. The enterprise value is $11.47 million.
Important Dates
The next estimated earnings date is Wednesday, May 20, 2026, before market open.
| Earnings Date | May 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Evogene has 9.89 million shares outstanding. The number of shares has increased by 38.21% in one year.
| Current Share Class | 12.10M |
| Shares Outstanding | 9.89M |
| Shares Change (YoY) | +38.21% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 0.73% |
| Owned by Institutions (%) | 1.71% |
| Float | 9.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.62 |
| Forward PS | 6.60 |
| PB Ratio | 0.84 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.98 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.54, with a Debt / Equity ratio of 0.18.
| Current Ratio | 4.54 |
| Quick Ratio | 3.96 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -87.82 |
Financial Efficiency
Return on equity (ROE) is -100.69% and return on invested capital (ROIC) is -54.69%.
| Return on Equity (ROE) | -100.69% |
| Return on Assets (ROA) | -28.77% |
| Return on Invested Capital (ROIC) | -54.69% |
| Return on Capital Employed (ROCE) | -83.05% |
| Weighted Average Cost of Capital (WACC) | 8.80% |
| Revenue Per Employee | $32,932 |
| Profits Per Employee | -$72,521 |
| Employee Count | 117 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 4.04 |
Taxes
In the past 12 months, Evogene has paid $1,000 in taxes.
| Income Tax | 1,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.13% in the last 52 weeks. The beta is 0.95, so Evogene's price volatility has been similar to the market average.
| Beta (5Y) | 0.95 |
| 52-Week Price Change | -21.13% |
| 50-Day Moving Average | 0.87 |
| 200-Day Moving Average | 1.12 |
| Relative Strength Index (RSI) | 49.74 |
| Average Volume (20 Days) | 124,606 |
Short Selling Information
The latest short interest is 239,261, so 2.78% of the outstanding shares have been sold short.
| Short Interest | 239,261 |
| Short Previous Month | 242,174 |
| Short % of Shares Out | 2.78% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.84 |
Income Statement
In the last 12 months, Evogene had revenue of $3.85 million and -$8.49 million in losses. Loss per share was -$1.08.
| Revenue | 3.85M |
| Gross Profit | -241,000 |
| Operating Income | -13.79M |
| Pretax Income | -13.50M |
| Net Income | -8.49M |
| EBITDA | -13.26M |
| EBIT | -13.79M |
| Loss Per Share | -$1.08 |
Full Income StatementBalance Sheet
The company has $12.96 million in cash and $2.20 million in debt, with a net cash position of $10.76 million or $1.09 per share.
| Cash & Cash Equivalents | 12.96M |
| Total Debt | 2.20M |
| Net Cash | 10.76M |
| Net Cash Per Share | $1.09 |
| Equity (Book Value) | 11.98M |
| Book Value Per Share | -0.01 |
| Working Capital | 12.19M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$13.50 million and capital expenditures -$135,000, giving a free cash flow of -$13.64 million.
| Operating Cash Flow | -13.50M |
| Capital Expenditures | -135,000 |
| Depreciation & Amortization | 524,000 |
| Net Borrowing | -526,000 |
| Free Cash Flow | -13.64M |
| FCF Per Share | -$1.38 |
Full Cash Flow StatementMargins
Gross margin is -6.25%, with operating and profit margins of -357.85% and -220.22%.
| Gross Margin | -6.25% |
| Operating Margin | -357.85% |
| Pretax Margin | -350.32% |
| Profit Margin | -220.22% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Evogene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.21% |
| Shareholder Yield | -38.21% |
| Earnings Yield | -84.03% |
| FCF Yield | -135.04% |
Analyst Forecast
The average price target for Evogene is $3.50, which is 326.83% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.50 |
| Price Target Difference | 326.83% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 25, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jul 25, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Evogene has an Altman Z-Score of -20.34 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -20.34 |
| Piotroski F-Score | 2 |
